Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics (Nasdaq: TARA) has granted inducement non-qualified stock options for 120,000 shares to Dr. Martín Sebastian Olivo, the new Chief Medical Officer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protara Therapeutics (Nasdaq: TARA) has granted inducement non-qualified stock options for 120,000 shares to Dr. Martín Sebastian Olivo, the new Chief Medical Officer. The options have an exercise price of $15.30 per share, aligning with Protara's closing price as of April 19, 2021. Vesting occurs over four years, with 25% vesting after one year and the remainder vesting monthly. This award, approved by the Compensation Committee, aligns with NASDAQ Listing Rule 5635(c)(4). Protara is focused on developing therapies for cancer and rare diseases.
Positive
- Inducement stock options granted to new Chief Medical Officer.
- Stock options provide incentive alignment with company performance.
Negative
- None.
Details
News Market Reaction – TARA
The recorded move for TARA in the trading session of this news was -3.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 120,000 shares of common stock to Martín Sebastian Olivo, M.D., Protara’s newly appointed Chief Medical Officer.
Each stock option has an exercise price per share equal to
The Compensation Committee of Protara’s Board of Directors approved the awards as an inducement material to the new employee’s employment in accordance with NASDAQ Listing Rule 5635(c)(4).
About Protara Therapeutics
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.